tiprankstipranks
Advertisement
Advertisement

Onelife Capital Advisors Triples Equity Base Through Rights Issue Allotment

Story Highlights
  • Onelife Capital Advisors has allotted 24 million rights shares at ₹15 each, expanding its equity base.
  • The rights issue lifts paid-up capital from ₹13.36 crore to ₹37.36 crore, boosting financial flexibility and growth capacity.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Onelife Capital Advisors Triples Equity Base Through Rights Issue Allotment

Claim 30% Off TipRanks

Onelife Capital Advisors Limited ( (IN:ONELIFECAP) ) has provided an update.

Onelife Capital Advisors Limited has approved the allotment of 24,000,000 rights equity shares with a face value of ₹10 at an issue price of ₹15 per share, including a premium of ₹5, under its ongoing rights issue. Following this allotment, the company’s paid-up equity share capital has risen significantly from ₹13.36 crore to ₹37.36 crore, marking a substantial equity base expansion that could strengthen its financial flexibility and market positioning for future business initiatives.

The rights issue allotment, finalized in consultation with BSE and the registrar KFin Technologies, reflects successful subscription and completion of a key capital-raising step. This enlarged capital structure may dilute existing holdings proportionally, but it also potentially enhances the company’s ability to pursue growth opportunities, support operations, and improve its standing in the competitive financial services sector.

More about Onelife Capital Advisors Limited

Onelife Capital Advisors Limited is an India-based financial services company listed on BSE and NSE, operating from Thane, Maharashtra. The firm is engaged in capital markets activities and advisory-related services, positioning itself within the broader financial and investment services industry.

Average Trading Volume: 12,012

Technical Sentiment Signal: Buy

Current Market Cap: 560.4M INR

Find detailed analytics on ONELIFECAP stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1